Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Bioventix PLC (BVXP.L)
Farnham, GB
Bioventix PLC focuses on the development, manufacturing, and global provision of sheep monoclonal antibodies (SMAs) for various diagnostic purposes. The company's extensive product line features purified SMAs that facilitate testing for critical areas such as thyroid conditions, vitamin D deficiencies, cardiac health markers, detection of drugs of abuse, fertility assessments, infectious diseases, oncology, and other diverse medical indications. Additionally, Bioventix PLC offers tailored contract SMA development and specialized recombinant services. The London, UK-based firm was established in 2003.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -2.90% | +8.06% | -10.67% | -12.07% | -42.74% | -55.03% | -58.64% | +61.45% | +181.51% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-3.6% Q4'25: -7.7% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%-6.5% Q4'25: -10.5% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%+56.6% Q4'25: +71.5% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%+76.8% ★ Q4'25: +74.1% (vs Q4'23)
-
ROIC Biotechnology: -16.1%+116.9% ★ Q4'25: +245.4% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%-0.1% ★ Q4'25: 0.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× ★ Q4'25: 0.00× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2015 actual |
Jun 2016 actual |
Jun 2017 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
4.33M
est: 4.20M (+3.2%)
|
5.52M
est: 5.30M (+4.1%)
|
7.25M
est: 7.06M (+2.6%)
|
8.75M
est: 8.00M (+9.4%)
|
9.29M
est: 9.00M (+3.2%)
|
10.31M
est: 10.10M (+2.1%)
|
10.93M
est: 11.10M (-1.5%)
|
11.72M
est: 10.40M (+12.7%)
|
12.82M
est: 12.80M (+0.1%)
|
13.61M
est: 14.00M (-2.8%)
|
13.12M
est: 13.50M (-2.8%)
|
12.50M
12.50M – 12.50M
-7.4% YoY
|
| EBITDA |
3.14M
est: 3.29M (-4.5%)
|
4.17M
est: 4.15M (+0.5%)
|
5.75M
est: 5.53M (+4.0%)
|
6.96M
est: 6.27M (+11.1%)
|
7.10M
est: 7.83M (-9.3%)
|
8.11M
est: 7.93M (+2.3%)
|
8.22M
est: 8.72M (-5.7%)
|
9.42M
est: 9.68M (-2.7%)
|
10.20M
est: 10.03M (+1.7%)
|
10.74M
est: 11.04M (-2.7%)
|
10.17M
est: 10.65M (-4.5%)
|
9.86M
9.86M – 9.86M
-7.4% YoY
|
| EBIT |
3.11M
est: 3.25M (-4.3%)
|
4.22M
est: 3.91M (+7.9%)
|
5.77M
est: 5.46M (+5.7%)
|
6.87M
est: 6.19M (+11.0%)
|
7.03M
est: 7.69M (-8.5%)
|
7.98M
est: 7.78M (+2.6%)
|
8.09M
est: 8.58M (-5.8%)
|
9.28M
est: 9.49M (-2.3%)
|
10.07M
est: 10.56M (-4.6%)
|
10.63M
est: 11.03M (-3.7%)
|
10.07M
est: 10.64M (-5.3%)
|
9.85M
9.85M – 9.85M
-7.4% YoY
|
| Net Income |
2.56M
est: 2.69M (-4.9%)
|
3.49M
est: 3.23M (+8.3%)
|
4.92M
est: 4.73M (+4.1%)
|
5.66M
est: 5.25M (+7.9%)
|
5.86M
est: 6.37M (-8.0%)
|
7.20M
est: 6.58M (+9.5%)
|
6.73M
est: 7.24M (-7.0%)
|
7.67M
est: 8.03M (-4.4%)
|
8.37M
est: 8.07M (+3.8%)
|
8.10M
est: 8.80M (-8.0%)
|
7.58M
est: 8.02M (-5.4%)
|
7.20M
7.20M – 7.20M
-10.2% YoY
|
| SGA |
915.2K
est: 316.8K (+188.9%)
|
892.5K
est: 399.8K (+123.2%)
|
1.07M
est: 532.6K (+100.1%)
|
1.31M
est: 603.4K (+117.7%)
|
1.40M
est: 678.8K (+106.6%)
|
223.1K
est: 1.57M (-85.8%)
|
428.0K
est: 837.2K (-48.9%)
|
731.6K
est: 1.92M (-61.9%)
|
612.4K
est: 965.5K (-36.6%)
|
970.9K
est: 1.06M (-8.1%)
|
2.05M
est: 1.02M (+101.5%)
|
942.8K
942.8K – 942.8K
-7.4% YoY
|
| EPS |
0.51
est: 0.51 (+0.4%)
|
0.69
est: 0.65 (+6.3%)
|
0.96
est: 0.89 (+7.5%)
|
1.10
est: 0.99 (+10.9%)
|
1.14
est: 1.12 (+1.4%)
|
1.39
est: 1.25 (+11.4%)
|
1.29
est: 1.37 (-5.7%)
|
1.47
est: 1.27 (+15.5%)
|
1.61
est: 1.52 (+5.6%)
|
1.55
est: 1.66 (-6.7%)
|
1.45
est: 1.52 (-4.3%)
|
1.36
1.36 – 1.36
-10.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-28 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-27 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-26 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-22 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-21 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-20 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-19 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-18 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-05 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-01 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Peter John Harrison | Chief Executive Officer & Director | 362.3K | male |
| Bruce Edward Heath Hiscock | Chief Financial Officer & Director | 105.8K | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BVXP.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
